Lapatinib potentiates cytotoxicity of  YM155 in neuroblastoma via inhibition of the ABCB1 efflux transporter

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Lapatinib potentiates cytotoxicity of  YM155 in neuroblastoma via inhibition of the ABCB1 efflux transporter. / Radic-Sarikas, Branka; Halasz, Melinda; Huber, Kilian V M; Winter, Georg E; Tsafou, Kalliopi P; Papamarkou, Theodore; Brunak, Søren; Kolch, Walter; Superti-Furga, Giulio.

In: Scientific Reports, Vol. 7, No. 1, 08.06.2017, p. 3091.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Radic-Sarikas, B, Halasz, M, Huber, KVM, Winter, GE, Tsafou, KP, Papamarkou, T, Brunak, S, Kolch, W & Superti-Furga, G 2017, 'Lapatinib potentiates cytotoxicity of  YM155 in neuroblastoma via inhibition of the ABCB1 efflux transporter', Scientific Reports, vol. 7, no. 1, pp. 3091. https://doi.org/10.1038/s41598-017-03129-6

APA

Radic-Sarikas, B., Halasz, M., Huber, K. V. M., Winter, G. E., Tsafou, K. P., Papamarkou, T., Brunak, S., Kolch, W., & Superti-Furga, G. (2017). Lapatinib potentiates cytotoxicity of  YM155 in neuroblastoma via inhibition of the ABCB1 efflux transporter. Scientific Reports, 7(1), 3091. https://doi.org/10.1038/s41598-017-03129-6

Vancouver

Radic-Sarikas B, Halasz M, Huber KVM, Winter GE, Tsafou KP, Papamarkou T et al. Lapatinib potentiates cytotoxicity of  YM155 in neuroblastoma via inhibition of the ABCB1 efflux transporter. Scientific Reports. 2017 Jun 8;7(1):3091. https://doi.org/10.1038/s41598-017-03129-6

Author

Radic-Sarikas, Branka ; Halasz, Melinda ; Huber, Kilian V M ; Winter, Georg E ; Tsafou, Kalliopi P ; Papamarkou, Theodore ; Brunak, Søren ; Kolch, Walter ; Superti-Furga, Giulio. / Lapatinib potentiates cytotoxicity of  YM155 in neuroblastoma via inhibition of the ABCB1 efflux transporter. In: Scientific Reports. 2017 ; Vol. 7, No. 1. pp. 3091.

Bibtex

@article{6cdb55f6619341b9a7cca5cc9216d452,
title = "Lapatinib potentiates cytotoxicity of  YM155 in neuroblastoma via inhibition of the ABCB1 efflux transporter",
abstract = "Adverse side effects of cancer agents are of great concern in the context of childhood tumors where they can reduce the quality of life in young patients and cause life-long adverse effects. Synergistic drug combinations can lessen potential toxic side effects through lower dosing and simultaneously help to overcome drug resistance. Neuroblastoma is the most common cancer in infancy and extremely heterogeneous in clinical presentation and features. Applying a systematic pairwise drug combination screen we observed a highly potent synergy in neuroblastoma cells between the EGFR kinase inhibitor lapatinib and the anticancer compound YM155 that is preserved across several neuroblastoma variants. Mechanistically, the synergy was based on a lapatinib induced inhibition of the multidrug-resistance efflux transporter ABCB1, which is frequently expressed in resistant neuroblastoma cells, which allowed prolonged and elevated cytotoxicity of YM155. In addition, the drug combination (i.e. lapatinib plus YM155) decreased neuroblastoma tumor size in an in vivo model.",
keywords = "Journal Article",
author = "Branka Radic-Sarikas and Melinda Halasz and Huber, {Kilian V M} and Winter, {Georg E} and Tsafou, {Kalliopi P} and Theodore Papamarkou and S{\o}ren Brunak and Walter Kolch and Giulio Superti-Furga",
year = "2017",
month = jun,
day = "8",
doi = "10.1038/s41598-017-03129-6",
language = "English",
volume = "7",
pages = "3091",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "nature publishing group",
number = "1",

}

RIS

TY - JOUR

T1 - Lapatinib potentiates cytotoxicity of  YM155 in neuroblastoma via inhibition of the ABCB1 efflux transporter

AU - Radic-Sarikas, Branka

AU - Halasz, Melinda

AU - Huber, Kilian V M

AU - Winter, Georg E

AU - Tsafou, Kalliopi P

AU - Papamarkou, Theodore

AU - Brunak, Søren

AU - Kolch, Walter

AU - Superti-Furga, Giulio

PY - 2017/6/8

Y1 - 2017/6/8

N2 - Adverse side effects of cancer agents are of great concern in the context of childhood tumors where they can reduce the quality of life in young patients and cause life-long adverse effects. Synergistic drug combinations can lessen potential toxic side effects through lower dosing and simultaneously help to overcome drug resistance. Neuroblastoma is the most common cancer in infancy and extremely heterogeneous in clinical presentation and features. Applying a systematic pairwise drug combination screen we observed a highly potent synergy in neuroblastoma cells between the EGFR kinase inhibitor lapatinib and the anticancer compound YM155 that is preserved across several neuroblastoma variants. Mechanistically, the synergy was based on a lapatinib induced inhibition of the multidrug-resistance efflux transporter ABCB1, which is frequently expressed in resistant neuroblastoma cells, which allowed prolonged and elevated cytotoxicity of YM155. In addition, the drug combination (i.e. lapatinib plus YM155) decreased neuroblastoma tumor size in an in vivo model.

AB - Adverse side effects of cancer agents are of great concern in the context of childhood tumors where they can reduce the quality of life in young patients and cause life-long adverse effects. Synergistic drug combinations can lessen potential toxic side effects through lower dosing and simultaneously help to overcome drug resistance. Neuroblastoma is the most common cancer in infancy and extremely heterogeneous in clinical presentation and features. Applying a systematic pairwise drug combination screen we observed a highly potent synergy in neuroblastoma cells between the EGFR kinase inhibitor lapatinib and the anticancer compound YM155 that is preserved across several neuroblastoma variants. Mechanistically, the synergy was based on a lapatinib induced inhibition of the multidrug-resistance efflux transporter ABCB1, which is frequently expressed in resistant neuroblastoma cells, which allowed prolonged and elevated cytotoxicity of YM155. In addition, the drug combination (i.e. lapatinib plus YM155) decreased neuroblastoma tumor size in an in vivo model.

KW - Journal Article

U2 - 10.1038/s41598-017-03129-6

DO - 10.1038/s41598-017-03129-6

M3 - Journal article

C2 - 28596528

VL - 7

SP - 3091

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

IS - 1

ER -

ID: 184322649